Business, Health Care

Bayer Phase IV study met its primary endpoint in PAH patients who had transitioned to Adempas® (riociguat) after insufficient response to PDE5 inhibitors

Data presented as a late-breaker during a virtual ALERT session at the annual meeting of the European Respiratory Society Outcomes from the randomized, controlled, open-label REPLACE study included results from 226 patients with pulmonary arterial hypertension (PAH) WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced

News Now!

Gov. Gavin Newsom declares state of emergency

The Gov. of California declared a statewide emergency as wildfires continue to burn severely in several counties. “We had to splash water on our hair because our hair was catching on fire,” one evacuee said of the harrowing escape from the Creek